Confo Therapeutics, the Ghent-based drug discovery company that uses single domain antibody fragments derived from camelid antibodies, has raised €30m in a Series A round. The funds will be used to accelerate its proprietary drug discovery activities and advance its pipeline of GPCR-modulating compounds to create drug candidates for clinical trials.
“The €30m will get the lead program to Phase I and continue to feed the pipeline to deliver clinical candidates...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
